www.EXFILE.com 888-775-4789 -- BOSTON SCIENTIFIC CORPORATION -- EXHIBIT 99.1 TO FORM 8K

“We were pleased with the quarter, especially with our expense management and working capital initiatives, which resulted in excellent earnings leverage and improved cash flow,” said Jim Tobin, President and Chief Executive Officer of Boston Scientific. “The performance of our CRM group was particularly impressive, with double-digit growth and a number of important product approvals, including FDA approval for the COGNIS CRT-D and the TELIGEN ICD, two breakthrough technologies. Our Neuromodulation and Endosurgery groups also posted double-digit increases. In addition, we have now received FDA approval of our PROMUSTM Everolimus-Eluting Coronary Stent System, making us the only company to offer two distinct drug platforms.”

Net sales for the second quarter of 2008 were $2.024 billion, including sales from divested businesses of $19 million and a reduction of $22 million in revenue as a result of recording an increase in our sales return reserve in anticipation of our new drug-eluting stent platforms, as compared to sales of $2.071 billion for the second quarter of 2007, including sales from divested businesses of $139 million.

Worldwide sales of the Company’s drug-eluting coronary stent systems for the second quarter of 2008 were $382 million, as compared to $437 million for the second quarter of 2007. U.S. sales of these systems were $175 million, as compared to $249 million. International sales of these systems were $207 million, as compared to $188 million. Worldwide sales of coronary stent systems were $440 million for the second quarter of 2008, as compared to $498 million for the second quarter of 2007. U.S. sales of these systems were $200 million, as compared to $275 million. International sales of these systems were $240 million, as compared to $223 million.

Worldwide sales of the Company’s CRM products for the second quarter of 2008 were $578 million, which included $420 million of implantable cardioverter defibrillator (ICD) sales, as compared to worldwide CRM sales of $524 million for the second quarter of 2007, which included $377 million of ICD sales. U.S. CRM product sales were $364 million, which included $276 million of ICD sales, as compared to $332 million, which included $253 million of ICD sales. International CRM sales were $214 million, which included $144 million of ICD sales, as compared to $192 million, which included $124 million of ICD sales.

Reported net income for the second quarter of 2008 was $98 million, or $0.07 per share. Reported results included acquisition-, divestiture- and restructuring-related charges and amortization expense (after-tax) of $206 million, or approximately $0.13 per share, which consisted of the following:

$96 million of pre-tax charges ($64 million after-tax), attributable to losses in connection with the sale of the Company’s non-strategic investments, which are expected to be partially offset by pre-tax gains of approximately $30 million ($20 million after-tax) when the transactions are completed in the second half of the year;

Reported net income for the second quarter of 2007 was $115 million, or $0.08 per share. Reported results for the second quarter of 2007 included acquisition-related charges and amortization expense (after-tax) of $127 million, or approximately $0.08 per share. Adjusted net income for the second quarter of 2007, excluding these charges, was $242 million, or $0.16 per share.

The Company estimates net sales for the third quarter of 2008 of between $1.950 billion and $2.060 billion. Adjusted net income, excluding acquisition-, divestiture-, litigation- and restructuring-related charges and amortization expense, is estimated to range between $0.14 and $0.19 per share. The Company estimates reported net income on a GAAP basis of between $0.18 and $0.23 per share. Included in the Company’s estimated reported net income on a GAAP basis is approximately $0.12 per share of gains associated with the receipt of an acquisition-related milestone payment, $0.01 per share of expected gains related to the sale of the Company’s non-strategic investments, $0.02 per share of restructuring-related costs and $0.07 per share of amortization expense.

Boston Scientific management will be discussing these results with analysts on a conference call at 8:30 a.m. (ET) Tuesday, July 22, 2008. The Company will webcast the call to all interested parties through its website: www.bostonscientific.com. Please see the website for details on how to access the webcast. The webcast will be available for one year on the Boston Scientific website.

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like “anticipate,” “expect,” “project,” “believe,” “plan,” “estimate,” “intend” and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our financial performance, our programs to increase shareholder value, new product approvals, acquisitions and divestitures, our growth strategy, market recovery and our market position. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties

that may affect our future operations, see Part I, Item IA- Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.


	Three Months Ended
	June 30,
In millions, except per share data	2008			2007

Net sales	$	2,024		$	2,071
Cost of products sold		604			563
Gross profit		1,420			1,508

Operating expenses
Selling, general and administrative expenses		655			752
Research and development expenses		253			275
Royalty expense		48			51
Amortization expense		135			158
Purchased research and development		16			(8	)
Restructuring charges		10
		1,117			1,228

Operating income		303			280

Other income (expense):
Interest expense		(118	)		(146	)
Other, net		(85	)		(8	)

Income before income taxes		100			126
Income tax expense		2			11
Net income	$	98		$	115


Net income per common share - assuming dilution	$	0.07		$	0.08

Weighted average shares outstanding - assuming dilution		1,505.2			1,499.9


	Three Months Ended				Three Months Ended
	June 30, 2008				June 30, 2007
In millions, except per share data	Net income		Impact per diluted share		Net income		Impact per diluted share
GAAP results	$	98	$	0.07	$	115	$	0.08
Non-GAAP adjustments:
Acquisition-related charges		19		0.01		2		—
Divestiture-related losses		64		0.04
Restructuring-related charges		15		0.01
Amortization expense		108		0.07		125		0.08
Adjusted results	$	304	$	0.20	$	242	$	0.16


	Three Months Ended
	June 30,
	2008			2007
Acquisition-related charges:
Purchased research and development	$	16		$	(8	)
Integration costs (a)					12
		16			4
Income tax expense (benefit) (d)		3			(2	)
Acquisition-related charges, net of tax	$	19		$	2

Divestiture-related losses:
Loss on sale of non-strategic investments (b)	$	96
Income tax benefit (d)		(32	)
Divestiture-related losses, net of tax	$	64

Restructuring-related charges:
Restructuring-related charges (c)	$	21
Income tax benefit (d)		(6	)
Restructuring-related charges, net of tax	$	15

Amortization expense:
Amortization expense	$	135		$	158
Income tax benefit (d)		(27	)		(33	)
Amortization expense, net of tax	$	108		$	125

(a) Recorded expenses of $8 million to selling, general and administrative expenses, $2 million to cost of products sold, and $2 million to research and development expenses.

(b) Recorded to other, net.

(c) Recorded $10 million to restructuring charges, $6 million to selling, general and administrative expenses, $3 million to cost of products sold, and $2 million to research and development expenses.

(d) Amounts are tax effected at the Company's effective tax rate, unless the amount is a significant unusual or infrequently occurring item in accordance with FASB Interpretation No. 18, "Accounting for Income Taxes in Interim Periods."


	Six Months Ended
	June 30,
In millions, except per share data	2008			2007

Net sales	$	4,071		$	4,157
Cost of products sold		1,185			1,131
Gross profit		2,886			3,026

Operating expenses
Selling, general and administrative expenses		1,315			1,487
Research and development expenses		497			564
Royalty expense		94			103
Amortization expense		279			312
Purchased research and development		29			(3	)
Restructuring charges		39
Gain on divestitures		(250	)
		2,003			2,463

Operating income		883			563

Other income (expense):
Interest expense		(249	)		(287	)
Other, net		(72	)		10

Income before income taxes		562			286
Income tax expense		142			51
Net income	$	420		$	235


Net income per common share - assuming dilution	$	0.28		$	0.16

Weighted average shares outstanding - assuming dilution		1,502.6			1,498.9


	Six Months Ended						Six Months Ended
	June 30, 2008						June 30, 2007
In millions, except per share data	Net income				Impact per diluted share		Net income		Impact per diluted share
GAAP results	$	420		$	0.28		$	235	$	0.16
Non-GAAP adjustments:
Acquisition-related charges		27			0.02			22		0.01
Divestiture-related gains		(51	)		(0.04	)
Restructuring-related charges		47			0.03
Amortization expense		218			0.15			247		0.17
Adjusted results	$	661		$	0.44		$	504	$	0.34


	Six Months Ended
	June 30,
	2008			2007
Acquisition-related charges:
Purchased research and development	$	29		$	(3	)
Integration costs (a)					24
Fair-value adjustment for the sharing of proceeds feature of the Abbott stock purchase (b)					8
		29			29
Income tax benefit (d)		(2	)		(7	)
Acquisition-related charges, net of tax	$	27		$	22

Divestiture-related gains:
Gain on divestitures	$	(250	)
Loss on sale of non-strategic investments (b)		96
		(154	)
Income tax expense (d)		103
Divestiture-related gains, net of tax	$	(51	)

Restructuring-related charges:
Restructuring-related charges (c)	$	65
Income tax benefit (d)		(18	)
Restructuring-related charges, net of tax	$	47

Amortization expense:
Amortization expense	$	279		$	312
Income tax benefit (d)		(61	)		(65	)
Amortization expense, net of tax	$	218		$	247

(a) Recorded expenses of $17 million to selling, general and administrative expenses, $4 million to cost of products sold, and $3 million to research and development expenses.

(b) Recorded to other, net.

(c) Recorded $39 million to restructuring charges, $15 million to selling, general and administrative expenses, $7 million to cost of products sold, and $4 million to research and development expenses.

(d) Amounts are tax effected at the Company's effective tax rate, unless the amount is a significant unusual or infrequently occurring item in accordance with FASB Interpretation No. 18, "Accounting for Income Taxes in Interim Periods."


	June 30,		December 31,
In millions	2008		2007
	(Unaudited)
Assets
Current assets:
Cash and cash equivalents	$	1,616	$	1,452
Trade accounts receivable, net		1,416		1,502
Inventories		812		725
Deferred income taxes		931		679
Assets held for sale				1,099
Other current assets		393		464
Total current assets		5,168		5,921

Property, plant and equipment, net		1,738		1,735
Investments		122		317
Other assets		113		157
Intangible assets, net		22,760		23,067
	$	29,901	$	31,197



Liabilities and Stockholders' Equity
Current liabilities:
Borrowings due within one year	$	271	$	256
Accounts payable and accrued expenses		2,421		2,680
Liabilities associated with assets held for sale				39
Other current liabilities		343		275
Total current liabilities		3,035		3,250

Long-term debt		7,014		7,933
Deferred income taxes		2,252		2,284
Other long-term liabilities		1,965		2,633

Stockholders' equity		15,635		15,097
	$	29,901	$	31,197

	Three Months Ended
	June 30,				Change
					As Reported		Constant
					Currency		Currency
In millions	2008		2007		Basis		Basis

DOMESTIC	$	1,088	$	1,118		(3%)		(3%)

EMEA		531		457		16%		3%
INTER-CONTINENTAL		386		357		8%		(3%)
INTERNATIONAL		917		814		13%		0%

DIVESTED BUSINESSES		19		139		N/A		N/A

WORLDWIDE	$	2,024	$	2,071		(2%)		(7%)

	Three Months Ended
	June 30,				Change
					As Reported		Constant
					Currency		Currency
In millions	2008		2007		Basis		Basis

INTERVENTIONAL CARDIOLOGY	$	707	$	741		(5%)		(11%)
PERIPHERAL INTERVENTION		154		153		0%		(4%)
CARDIOVASCULAR		861		894		(4%)		(9%)

NEUROVASCULAR		92		88		4%		(5%)
PERIPHERAL EMBOLIZATION		23		25		(2%)		(8%)
NEUROVASCULAR		115		113		2%		(5%)

CARDIAC RHYTHM MANAGEMENT		578		524		10%		5%
ELECTROPHYSIOLOGY		38		36		5%		1%
CARDIAC RHYTHM MANAGEMENT		616		560		10%		5%

ENDOSCOPY		243		214		13%		7%
UROLOGY		109		100		9%		7%
ENDOSURGERY		352		314		12%		7%

NEUROMODULATION		61		51		20%		19%

DIVESTED BUSINESSES		19		139		N/A		N/A

WORLDWIDE	$	2,024	$	2,071		(2%)		(7%)

	Six Months Ended
	June 30,				Change
					As Reported		Constant
					Currency		Currency
In millions	2008		2007		Basis		Basis

DOMESTIC	$	2,205	$	2,287		(4%)		(4%)

EMEA		1,039		926		12%		(1%)
INTER-CONTINENTAL		776		670		16%		4%
INTERNATIONAL		1,815		1,596		14%		1%

DIVESTED BUSINESSES		51		274		N/A		N/A

WORLDWIDE	$	4,071	$	4,157		(2%)		(7%)

	Six Months Ended
	June 30,				Change
					As Reported		Constant
					Currency		Currency
In millions	2008		2007		Basis		Basis

INTERVENTIONAL CARDIOLOGY	$	1,463	$	1,518		(4%)		(9%)
PERIPHERAL INTERVENTION		309		299		3%		(2%)
CARDIOVASCULAR		1,772		1,817		(2%)		(8%)

NEUROVASCULAR		184		179		3%		(5%)
PERIPHERAL EMBOLIZATION		46		46		0%		(6%)
NEUROVASCULAR		230		225		2%		(5%)

CARDIAC RHYTHM MANAGEMENT		1,143		1,062		8%		3%
ELECTROPHYSIOLOGY		76		73		5%		2%
CARDIAC RHYTHM MANAGEMENT		1,219		1,135		7%		3%

ENDOSCOPY		472		420		12%		6%
UROLOGY		209		195		7%		5%
ENDOSURGERY		681		615		11%		6%

NEUROMODULATION		118		91		29%		28%

DIVESTED BUSINESSES		51		274		N/A		N/A

WORLDWIDE	$	4,071	$	4,157		(2%)		(7%)


	Q2 2008 Net Sales as compared to Q2 2007
	Change						Estimated Impact
In millions	As Reported Currency Basis			Constant Currency Basis			of Foreign Currency

DOMESTIC	$	(30	)	$	(30	)	$	—

EMEA		74			12			62
INTER-CONTINENTAL		29			(12	)		41
INTERNATIONAL		103			—			103

DIVESTED BUSINESSES		(120	)		(122	)		2

WORLDWIDE	$	(47	)	$	(152	)	$	105

Q2 2008 Net Sales as compared to Q2 2007

Change

Estimated Impact

In millions

As Reported Currency Basis

Constant Currency Basis

of Foreign Currency


INTERVENTIONAL CARDIOLOGY	$	(34	)	$	(77	)	$	43
PERIPHERAL INTERVENTIONS		1			(6	)		7
CARDIOVASCULAR		(33	)		(83	)		50

NEUROVASCULAR		4			(3	)		7
PERIPHERAL EMBOLIZATION		(2	)		(4	)		2
NEUROVASCULAR		2			(7	)		9

CARDIAC RHYTHM MANAGEMENT		54			28			26
ELECTROPHYSIOLOGY		2			1			1
CARDIAC RHYTHM MANAGEMENT		56			29			27

ENDOSCOPY		29			15			14
UROLOGY		9			6			3
ENDOSURGERY		38			21			17

NEUROMODULATION		10			10			—

DIVESTED BUSINESSES		(120	)		(122	)		2

WORLDWIDE	$	(47	)	$	(152	)	$	105


	Q2 2008 YTD Net Sales as compared to Q2 2007
	Change						Estimated Impact
In millions	As Reported Currency Basis			Constant Currency Basis			of Foreign Currency

DOMESTIC	$	(82	)	$	(82	)	$	—

EMEA		113			(4	)		117
INTER-CONTINENTAL		106			23			83
INTERNATIONAL		219			19			200

DIVESTED BUSINESSES		(223	)		(227	)		4

WORLDWIDE	$	(86	)	$	(290	)	$	204


	Q2 2008 YTD Net Sales as compared to Q2 2007
	Change						Estimated Impact
In millions	As Reported Currency Basis			Constant Currency Basis			of Foreign Currency

INTERVENTIONAL CARDIOLOGY	$	(55	)	$	(137	)	$	82
PERIPHERAL INTERVENTIONS		10			(6	)		16
CARDIOVASCULAR		(45	)		(143	)		98

NEUROVASCULAR		5			(9	)		14
PERIPHERAL EMBOLIZATION		—			(3	)		3
NEUROVASCULAR		5			(12	)		17

CARDIAC RHYTHM MANAGEMENT		81			30			51
ELECTROPHYSIOLOGY		3			1			2
CARDIAC RHYTHM MANAGEMENT		84			31			53

ENDOSCOPY		52			25			27
UROLOGY		14			9			5
ENDOSURGERY		66			34			32

NEUROMODULATION		27			27			—

DIVESTED BUSINESSES		(223	)		(227	)		4

WORLDWIDE	$	(86	)	$	(290	)	$	204

	Q3 2008 Estimate			Q3 2008 Estimate
	(Low)			(High)
GAAP results	$	0.18		$	0.23

Estimated acquisition-related gains		(0.12	)		(0.12	)
Estimated divestiture-related gains		(0.01	)		(0.01	)
Estimated restructuring-related charges		0.02			0.02
Estimated amortization expense		0.07			0.07

Adjusted results	$	0.14		$	0.19

To supplement Boston Scientific’s condensed consolidated financial statements presented on a GAAP basis; the Company discloses certain non-GAAP measures that exclude certain amounts, including non-GAAP net income, non-GAAP net income per diluted share, and regional and divisional revenue growth rates that exclude the impact of foreign exchange. These non-GAAP measures are not in accordance with, or an alternative for, generally accepted accounting principles in the United States.

The GAAP measure most comparable to non-GAAP net income is GAAP net income and the GAAP measure most comparable to non-GAAP net income per diluted share is GAAP net income per diluted share. Reconciliations of each of these non-GAAP financial measures to the corresponding GAAP measure are included in the accompanying schedules.

To calculate regional and divisional revenue growth rates that exclude the impact of foreign exchange, the Company converts actual current-period net sales from local currency to U.S. dollars using constant foreign exchange rates. The GAAP measure most comparable to this non-GAAP measure is growth rate percentages based on GAAP revenue. A reconciliation of this non-GAAP financial measure to the corresponding GAAP measure is included in the accompanying schedules.

Management uses these supplemental non-GAAP measures to evaluate performance period over period, to analyze the underlying trends in the Company’s business, to assess its performance relative to its competitors, and to establish operational goals and forecasts that are used in allocating resources. In addition, management uses these non-GAAP measures to further its understanding of the performance of the Company’s operating segments. The adjustments excluded from the Company’s non-GAAP measures are consistent with those excluded from its reportable segments’ measure of profit or loss. These adjustments are excluded from the segment measures that are reported to the Company’s chief operating decision maker and are used to make operating decisions and assess performance.

The following is an explanation of each of the adjustments that management excluded as part of its non-GAAP measures for the three and six month periods ending June 30, 2008 and June 30, 2007 and for the forecasted three month period ending September 30, 2008, as well as reasons for excluding each of these individual items:

Acquisition-related (gains) charges - These adjustments consist of purchased research and development, integration costs associated with the Company’s acquisition of Guidant, a fair value adjustment related to the sharing of proceeds feature of the Abbott stock purchase, and a gain associated with the receipt of an acquisition-related milestone payment. Purchased research and development is a highly variable charge based on valuation assumptions. Management removes the impact of purchased research and development from the Company's operating results to assist in assessing the Company's operating performance and cash generated from operations. The integration costs associated with the Company’s acquisition of Guidant do not reflect expected on-going future operating expenses. The fair value adjustment related to the sharing of proceeds feature of the Abbott stock purchase is a non-cash adjustment and is not indicative of the Company's on-going operations. The gain on the acquisition-related milestone payment, recorded in the third quarter of 2008, is not indicative of future operating performance and will not be used by management in assessing the Company’s operating performance. Accordingly, management excluded these amounts for purposes of calculating these non-GAAP measures to facilitate an evaluation of the Company's current operating performance and a comparison to the Company's past operating performance.

Divestiture-related (gains) losses – These amounts represent gains and losses that the Company recognized related to the sale of non-strategic assets, including the sale of certain businesses, development programs and non-strategic investments. The sale and transfer of these non-strategic assets are expected to be substantially completed during 2008. These gains and losses are not indicative of future operating performance and are not used by management to assess operating performance. Accordingly, management excluded these amounts for purposes of calculating these non-GAAP measures to facilitate an evaluation of the Company's current operating performance and a comparison to the Company's past operating performance.

Restructuring-related charges – These adjustments primarily represent employee-related termination benefits, employee-related retention costs, asset write-downs and other costs associated with the Company’s restructuring initiatives. These expenses are not indicative of the Company’s on-going operating performance and are excluded by management in assessing the Company’s operating performance, and are also excluded from the Company’s operating segments’ measures of profit and loss used for making operating decisions and assessing performance. Accordingly, management excluded these charges for purposes of calculating these non-GAAP measures to facilitate an evaluation of the Company's current operating performance and a comparison to the Company's past operating performance.

Amortization expense - Amortization expense is a non-cash charge and does not impact the Company’s liquidity or compliance with the covenants included in its debt agreements. Following the Company’s acquisition of Guidant, and the related increase in the Company’s debt, management has heightened its focus on cash generation and debt pay down. Management removes the impact of amortization from the Company’s operating performance to assist in assessing the Company’s cash generated from operations. Management believes this is a critical metric for the Company in measuring the Company’s ability to generate cash and pay down debt. Therefore, amortization expense is excluded from management’s assessment of operating performance, including the Company's operating segments' measure of profit and loss, and is also excluded from the measures management uses to set employee compensation. Accordingly, management believes this may be useful information to users of its financial statements and therefore has excluded these charges for purposes of calculating these non-GAAP measures to facilitate an evaluation of the Company’s current operating performance, particularly in terms of liquidity.

Foreign exchange on net sales - The impact of foreign exchange is highly variable and difficult to predict. Accordingly, management excludes the impact of foreign exchange for purposes of reviewing regional and divisional revenue growth rates to facilitate an evaluation of the Company’s current operating performance and comparison to the Company’s past operating performance.

Non-GAAP net income, non-GAAP net income per diluted share, and regional and divisional revenue growth rates that exclude the impact of foreign exchange may have limitations as analytical tools, and these non-GAAP measures should not be considered in isolation or as a replacement for GAAP financial measures. Some of the limitations associated with the use of these non-GAAP financial measures are:

Items such as purchased research and development, divestiture-related gains and losses, and the fair value adjustment related to the sharing of proceeds feature of the Abbott stock purchase reflect economic costs to the Company and are not reflected in non-GAAP net income and non-GAAP net income per diluted share.

Items such as amortization of purchased intangible assets, though not directly affecting Boston Scientific’s cash flow position, represent a reduction in value of intangible assets over time. The expense associated with this reduction in value is not included in Boston Scientific’s non-GAAP net income or non-GAAP net income per diluted share and therefore these measures do not reflect the full economic effect of the reduction in value of those intangible assets.

·	Other companies may calculate non-GAAP net income, non-GAAP net income per diluted share, or regional and divisional revenue growth rates that exclude the impact of foreign exchange differently than Boston Scientific does, limiting the usefulness of those measures for comparative purposes.

Boston Scientific compensates for the limitations on its non-GAAP financial measures by relying upon its GAAP results to gain a complete picture of the Company’s performance. The non-GAAP numbers focus instead upon the core business of the Company, which is only a subset, albeit a critical one, of the Company’s performance.

The Company believes that presenting non-GAAP net income, non-GAAP net income per share, and regional and divisional revenue growth rates that exclude the impact of foreign exchange in addition to the related GAAP measures provides investors greater transparency to the information used by Boston Scientific management for its financial and operational decision-making and allows investors to see Boston Scientific’s results “through the eyes” of management. The Company further believes that providing this information better enables Boston Scientific’s investors to understand the Company’s operating performance and to evaluate the methodology used by management to assess and measure such performance.